

Patient support & information through the website

In 2016 165,000 users visited the Anticancer Fund website. The website contains information on the Anticancer Fund projects and information sheets for patients on therapies. On top of that over 150 patients received personalised information via info@anticancerfund.org. The guides for patients with general information were updated and new detailed information per cancer type was added.

Partnerships




A new collaboration between Seerave, a UK-based foundation, and the Anticancer Fund has been established in 2016 to manage research on non-toxic interventions which could improve the survival and/or the quality of life of melanoma patients.



After a successful collaboration in 2015, the partnership between OvaCure (a Danish non-profit organisation focused on the fight against ovarian cancer) and the Anticancer Fund continued in 2016. The Anticancer Fund is the scientific strategy partner and a member of the OvaCure Scientific and Clinical Advisory Board. (www.ovacure.org)

FINANCE

For every Euro we spend...



Total amount* of € 2,0M well spent on the fight against cancer!

* Anticancer Fund expenses, which also covers all project costs of the Swiss, non-profit organisation Reliable Cancer Therapies managed by the Anticancer Fund



Address Anticancer Fund, Boechoutlaan 221,
1853 Strombeek-Bever, Belgium

Tel. +32 (0)2 268 48 16

Email info@anticancerfund.org

Website www.anticancerfund.org

Support us BE79 5230 8061 2533 - BIC TRIOBEBB



Expanding **TREATMENT OPTIONS**
for **CANCER PATIENTS**

ANNUAL IMPACT SHEET 2016

VISION & MISSION

MAIN ACTIVITIES

Research projects
Status 2016 - Applications - Drug repurposing
Patient support
Partnerships

FINANCE

Our vision

- The Anticancer Fund is dedicated to expanding the range of treatment options available to patients, regardless of their commercial value.

Our dual mission

- Developing promising cancer treatments that are currently neglected and bringing the most valuable treatments to the patient as quickly as possible.
- Providing free comprehensive, evidence-based information about cancer treatments.

MAIN ACTIVITIES

Research projects – status 2016

Cancer type	Nr. of patients	Project info	Country	Status
Brain	35	Fluvabrex: A phase I study assessing the safety of the association of fluvastatin in addition to celecoxib in children with refractory optic-pathway glioma	France	Ongoing study – including patients
Bone	26	Metzolimos: A phase Ib study assessing a combination of 4 re-purposed drugs in patients with advanced solid tumour with bone metastasis and advanced pre-treated osteosarcoma	France	Ongoing study – including patients
Breast	134	B-AHEAD-3: A randomised phase II trial to determine the effect of a 2-day calorie/energy restricted diet in overweight women with advanced breast cancer	UK	Ongoing study – including patients
Lung	86	Modulung: A prospective phase II, randomised multi-centre trial of a biomodulatory treatment with 3 oral drugs in patients with non-small cell lung cancer after platin failure	Germany	Ongoing study – including patients
Brain	10	CUSP9v3: A combination of 9 repurposed drugs for the treatment of recurrent glioblastoma	Germany	Ongoing study – including patients
Breast	149	Pioneer: A randomised phase II trial in early stage operable ER+ breast cancer patients who will receive 2 weeks of drug treatment prior to surgery	UK	In preparation
Colon	400	Aspirin trial: A phase III double-blind placebo-controlled randomised trial of adjuvant low-dose acetylsalicylic acid in curatively operated, stage II and III colon cancer patients	Belgium (& the Netherlands including 1,188 patients)	In preparation
Uterus	43	PRIMMO: A phase II investigation of pembrolizumab (Keytruda®) in combination with radiation and an immune modulatory cocktail in patients with advanced and/or refractory cervical cancer, endometrial carcinoma or uterine sarcoma	Belgium	In preparation
Leukaemia	76	AML-VIVA: A randomised phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients with acute myeloid leukaemia (AML) who are refractory to standard induction chemotherapy	Germany	In preparation
Breast	200	Perioperative ketorolac during breast cancer surgery in high-risk patients with and without inflammation. A prospective, randomised, placebo-controlled clinical trial	Belgium	Completed – awaiting results (inclusion closed)
Lung	60	Nitroglycerin as a radio-sensitizer in the treatment of non-small cell lung cancer: a phase II trial	The Netherlands	Completed – awaiting results (inclusion closed)
Melanoma	12	Treatment of patients with metastatic melanoma with ultra-low dose paclitaxel (Taxol®): a pilot trial for “proof of principle”	Germany	Completed with results ⁽¹⁾
All comers	16	Boost your Mind: Mindfulness for young adults after cancer treatment	Belgium	Completed with results ⁽²⁾
Uterus	n.a.	EFFECT: Effectiveness of Endometrial Cancer Treatments	Belgium	Completed with results ⁽³⁾
Ovarian	6	Phase I adoptive T-Cell therapy based on tumour infiltrating lymphocytes in women with stage IV ovarian cancer with recurrent or progressive disease	Denmark	Completed with results ⁽⁴⁾
Pancreatic	n.a.	Testing promising drug combinations in experimental mouse models of pancreatic cancer	USA	Ongoing study
Colon	10 (3 completed)	Vagus Nerve Stimulation: pilot trial: matched randomised-controlled trial in patients with advanced colon cancer (stage IV) aimed to extend the investigation of the role of vagal activity in cancer prognosis	Belgium	No further investment
All comers	9 (4 completed)	Non-randomized, single arm phase I/II study evaluated the safety and efficacy of adjuvant therapy with sodium bicarbonate for tumour-related pain	USA	No further investment
Liver	15 (0 completed)	A phase I dose-escalation study evaluated the safety and pharmacokinetics of oral artesanate in hepatocellular carcinoma	Belgium	No further investment
Uterus	n.a.	Verlest Uterine Cancer Fund at KULeuven (University of Leuven)	Belgium	Ongoing – explorative

Legend:

- Cancer Drug repurposing
- Non-cancer Drug repurposing
- Immunotherapy and non-cancer Drug repurposing
- Immunotherapy
- Complementary treatment
- Perioperative intervention
- Observational study
- Preclinical study

(1) Manuscript in preparation. Follow-up study under discussion.

(2) Publication available: Van der Gucht, K.; et al. A Mindfulness-Based Intervention for Adolescents and Young Adults After Cancer Treatment: Effects on Quality of Life, Emotional Distress, and Cognitive Vulnerability. *Journal of Adolescent and Young Adult Oncology*. 2016 Dec 21.

(3) Report available: www.kankerregister.org/media/docs/Projecten/Effect/NL/EFFECT_FB2015_General.pdf

(4) Safety and feasibility demonstrated. Follow-up study under discussion

The Anticancer Fund received 21 project applications in 2016

The Anticancer Fund is the preferred scientific partner for many international institutions and researchers. In 2016, 21 international project applications were registered at the Anticancer Fund. 1 project request on refractory paediatric solid tumours will be partially supported by the Anticancer Fund and is planned to be launched in 2017. 4 project applications are still under evaluation.


Repurposing Drugs in Oncology

The Repurposing Drugs in Oncology (ReDO) project is a collaboration with the US not-for-profit organisation Global Cures. The aim of the project is to identify a range of existing non-cancer drugs which show strong evidence of anti-cancer activity and which have the potential for added therapeutic value in clinical use.

The ReDO project identified a number of drugs in 2015 and published 3 articles. 2 additional articles on Diclofenac (doi:10.3332/ecancer.2016.610) and Propranolol (doi:10.3332/ecancer.2016.680) were published in 2016 in the *ecancermedicalsecience*, an open access peer-reviewed cancer journal.

The Anticancer Fund team is continuously building expertise in the field of drug repurposing resulting in the design of 2 clinical trials (pancreatic cancer and rectal cancer). These trials were debated with experts in the field willing to take the trial on.

In November 2016, the Anticancer Fund publication 'Repurposing Drugs for cancer treatment: unlocking the potential' became available online. It summarises the need for innovative policy actions in the current medicines regulatory sphere, in order to unlock the enormous potential of drug repurposing for patients, health systems, and societies at large. The Anticancer Fund actively urges health policymakers at European and national level to engage with all relevant stakeholders, including not-for-profit foundations, researchers, patient organisations, regulators, health technology assessment (HTA) authorities, and payers to act collaboratively on these actions.



On December 12th 2016, Orphan Drug Designation (EU/3/16/1805) was granted by the European Commission to the Anticancer Fund for propranolol for the treatment of soft tissue sarcoma. Propranolol is commonly used to treat high blood pressure. The Orphan Drug Designation will allow the Anticancer Fund to obtain protocol assistance from EMA to design optimal confirmatory clinical trials, the next step in the process. If positive results are obtained from these trials, the drug label of propranolol could be extended to the treatment of soft tissue sarcoma.